Influ2 Raises Millions in Seed Funding
Influ2, client of Inna Efimchik, raises funding to help B2B marketers expand into person-based marketing solutions.
Influ2, the first person-based advertising platform, today announced its initial round of seed funding of $3.4 million, which is the largest round of seed funding secured in the history of account-based marketing (ABM). Co-founded by Dmitri Lisitski, chief executive officer, and Vladimir Mikhalko, chief technology officer, Influ2 offers account-based advertising solutions that empower B2B marketers to only show their ads to chosen decision makers on an individualized basis.
This round of funding signifies Influ2’s commitment to person-based marketing solutions and the future of advertising. One of the biggest challenges that marketers often face is that they don’t know who is clicking on their ads, so the amount of clicks doesn’t convert into leads. Also, the ad experience can be annoying and disruptive, and doesn’t consider the person who is receiving the ad. So, the result is being ignored, deleted, overlooked and losing leads.
That’s why Influ2’s unique advertising platform identifies every ad visitor and takes into account the actual person who specifically clicked on the ad, how many times they interacted with the content of the ad and the time of which they engaged with the ad. This not only helps marketers identify interested decision-makers, but also allows them to develop more thoughtful and engaging ads that result in 4-7xs increased leads.
“With Influ2 I saw an opportunity to take a smarter approach to marketing. One that considers the person who is receiving the ad, and that’s the whole concept behind person-based marketing. It doesn’t replace or erase the concept of account-based marketing, it enhances it,” said Dmitri Lisitski. “And our rapid growth this past year shows that enterprises are eager to integrate this approach into their overall marketing strategies - especially since the traditional approaches to marketing, such as trade shows, are no longer available. Marketers have been more willing to innovate and embrace new trends, and person-based advertising is at the forefront of that.”
The round of funding was led by Boston fund One Way Ventures and Athens-based VentureFriends, as well as notable investors like super angel Murat Abdurakhamanov and Peter Harrison, former CEO of GlobalLogic. With over 57 clients globally, spanning Fortune 500 B2B enterprises such as Cato Networks, Hexaware, NVIDIA and high-tech MLEs, Influ2 plans to use this funding to expand its functionalities, bring in senior sales hires and to grow its client base in the healthcare and IT verticals.
“We’re proud to be leading this round and backing this seasoned team, along with a number of other great investors including leading funds and angels. We believe in Influ2's platform and clearly the timing could not be better for people to get access to such a product,” said Semyon Dukach, founding partner of One Way Ventures.
Having transformed the marketing space, Influ2 has been experiencing a period of rapid growth. It’s overall revenue has increased 5xs since 2019, and in the first six months of 2020 the company has experienced 251% growth despite the economic impact that COVID-19 has had on the global economy.
Influ2 has already integrated with all major CRMs and is poised to continue its rapid growth and expansion throughout 2020. To learn more or request a demo, please go to https://www.influ2.com.
About Influ2
Influ2 is a VC-backed, person-based advertising platform for B2B marketers, and it addresses the fundamental orchestration dissonance between advertising activities and sales. It delivers effective content marketing, as well as creates meaningful relationships with customers that result in closed deals. With Influ2 each step of the customer journey (from top-of-the-funnel brand awareness and demand generation stages to sales and customer retention efforts) is fortified by personally targeted advertising. The company is headquartered in New York, New York. For more information, visit https://www.influ2.com.